Krystal Biotech, Inc. is a clinical-stage biotechnology company that specializes in gene therapy for rare diseases. It shows the highest growth potential among its peers, with a target price difference of 38.70%. Currently, KRYS is priced at $181.47, with a target price of $251.70, indicating a more optimistic outlook from analysts.
Mersana Therapeutics, Inc. is another peer in the biotechnology sector, focusing on developing antibody-drug conjugates for cancer treatment. However, MRSN has a negative target price difference, suggesting a less favorable outlook compared to Krystal Biotech. Its stock is priced at $9.24, reflecting the challenges it faces in the market.
Overall, Krystal Biotech stands out among its peers with the most optimistic growth potential. Its focus on gene therapy for rare diseases and the significant target price difference highlight its promising position in the biotechnology sector.
